Hainan Shuangcheng Pharmaceuticals Co., Ltd., commonly referred to as Shuangcheng Pharma, is a prominent player in the pharmaceutical industry, headquartered in Hainan, China. Established in 2001, the company has made significant strides in the development and production of high-quality pharmaceutical products, particularly in the fields of active pharmaceutical ingredients (APIs) and finished dosage forms. With a strong operational presence across various regions in China and beyond, Shuangcheng Pharma is renowned for its commitment to innovation and quality. The company’s core offerings include a diverse range of APIs and formulations that cater to both domestic and international markets. Notably, Shuangcheng has achieved several industry certifications, underscoring its dedication to maintaining rigorous quality standards. As a result, it has secured a competitive position within the global pharmaceutical landscape, recognised for its reliability and excellence in service delivery.
How does Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hainan Shuangcheng Pharmaceuticals Co., Ltd., headquartered in China, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Hainan Shuangcheng Pharmaceuticals may not have established formal commitments to address carbon emissions or climate change initiatives at this time. As the pharmaceutical industry increasingly prioritises sustainability, it will be essential for the company to consider developing and communicating its climate strategies in the future.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Hainan Shuangcheng Pharmaceuticals Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
